Work

Serial Circulating Tumour Cell Monitoring During Androgen Deprivation and Docetaxel Therapies Identifies Poor Prognostic Metastatic Prostate Cancer

Year: 2026
Type: article
Abstract: Background/Objectives: Adding docetaxel to androgen deprivation therapy (ADT) prolongs survival in metastatic prostate cancer, but not all patients benefit, and no early biomarker identifies individuals with resistant disease. We assessed whether serial circulating tumour cell (CTC) sampling adds prognostic information beyond a pre-treatment sample. Methods: CTCs were enriched by size and deformability (Parsortix®) and phenotyped as epithelial (CK+/VIM−/CD45−), mesenchymal (CK−/VIM+/CD45−), or EMTing (CK+/VIM+/CD45−) at four time points in 61 patients treated with ADT and docetaxel (43 hormone-sensitive; 18 resistant, exploratory). Results: With longer follow-up, our previously reported baseline CTC predictors remained associated with overall survival (OS). In hormone-sensitive patients, baseline ≥ 6 total (HR 3.21, p = 0.007) and epithelial CTCs (p = 0.017) were associated with shorter OS. Across baseline, early, and late treatment, the OS hazard ratio for epithelial CTCs fell (2.59, 2.29, 2.11), yet for ≥3 mesenchymal CTCs rose (1.99, 2.99, 4.08). No single time point result survived false-discovery-rate correction. During early treatment, radiographic responders had fewer mesenchymal CTCs than non-responders (median 0 vs. 2.5, p = 0.032), whereas PSA did not differ (p = 0.642). Persistence of ≥3 mesenchymal CTCs from baseline to late treatment identified the poorest outcome (n = 3; median OS 17.3 months vs. not reached) and survived false-discovery-rate correction (q = 0.019). Late treatment mesenchymal CTCs added value to baseline PSA (p = 0.024) and ALP (p = 0.019) and added potential value to the best baseline marker (≥6 CTCs, p = 0.125), identifying some high-risk patients with baseline < 6 CTCs. Conclusions: Early on-treatment CTC samples may help predict response, while late treatment mesenchymal CTCs may add to baseline clinical markers. These hypothesis-generating findings require validation in a larger prospective cohort.
Source: Cancers
Language: English
Subfield: Cancer Research
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7235247992
FWCI:
Cites: 49
Cited by:
Related to: 10